Pembrolizumab, Decitabine +/- Venetoclax
Phase 1b Study of Pembrolizumab, Decitabine +/- Venetoclax Combination Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 54 patients (estimated)
- Sponsors
- City of Hope Medical Center
- Collaborators
- National Cancer Institute (NCI)
- Tags
- BCL-2 Inhibitor, Checkpoint Inhibitor, Hypomethylating Agents (HMA), Monoclonal Antibody, Programmed Death Receptor-1 (PD-1), Doublet Therapy
- Trial Type
- Treatment
- Last Update
- 1 month ago
- SparkCures ID
- 1516
- NCT Identifier
- NCT03969446
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.